Get started Log in

ALZ — Alzinova AB Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
SEK84.45m
Enterprise Value
SEK73.87m
Revenue

Brief: Alzinova Q4 Pretax Loss Widens To SEK 2.5 Million
24/02/2022 07:12
Brief: Alzinova To Receive Proceeds Of SEK 2.8 Mln
10/02/2022 07:42
Brief: Alzinova Says Preclinical Data Confirms Specificity, Efficacy Of ALZ-201
15/12/2021 07:09
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 1.5 Mln
28/10/2021 07:14
Brief: Alzinova receives approval to start first clinical study with ALZ-101 vaccine in patients with Alzheimer's disease
30/09/2021 14:57
Brief: Alzinova Q2 Loss After Financial Items Widens To SEK 2.2 Mln
26/08/2021 07:29
Brief: Alzinova Q2 Pretax Loss Widens To SEK 2.2 Mln
26/08/2021 07:23
Brief: Alzinova Q1 Pre-Tax Loss Narrows To SEK 1.5 Mln
19/05/2021 07:16
Brief: Alzinova: Status Update Regarding Application To Start Clinical Study With ALZ-101
22/04/2021 07:04
Brief: Alzinova Q4 Pretax Loss Narrows To SEK 2.4 Mln
25/02/2021 07:17
Brief: Alzinova: Drug Substance For ALZ-101 Vaccine Meets Requirements Of Upcoming Clinical Phase 1B Study
08/01/2021 07:03
Brief: Alzinova Announces Upcoming Clinical Study With Vaccine Candidate ALZ-101
04/11/2020 12:17
Brief: Alzinova Q3 Pretax Loss Widens To Sek 1.2 Million
29/10/2020 07:06
Brief: Alzinova Says Rights Issue Heavily Oversubscribed
20/10/2020 08:43
Brief: Alzinova Gets Positive Feedback From Finnish Medicines Agency Fimea
15/10/2020 07:07
Brief: Alzinova Carries Out 95 Percent Guaranteed Rights Issue Of Units Of About SEK 50 Mln
18/09/2020 07:37
Brief: Alzinova Q2 Pretax Loss Narrows To SEK 1.1 Million
26/08/2020 07:17
Brief: Alzinova: Delay In The Supply Of Material For The Clinical Trial Due To Additional Analytical Work
21/08/2020 07:11
Brief: Alzinova Q1 Pretax Loss Widens To SEK 1.8 Million
15/05/2020 07:10
Brief: Alzinova Appoints Håkan Skogström CFO
05/03/2020 07:02